AxoGen, Inc.
Industry
- Medical Devices
- Biomaterials
- Implantable Devices
- Biotechnology
Latest on AxoGen, Inc.
The US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
With 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe
The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
One-third of all the regenerative medicine advanced therapy (RMAT) designations granted by the US Food and Drug Administration’s Center for Biologics Evaluation and Research were awarded in fiscal yea